Kamran Alam's Insider Trades & SAST Disclosures
Kamran Alam's most recent trade in Taysha Gene Therapies Inc was a trade of 29,843 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on March 11, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Kamran Alam.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.69 per share. | 11 Mar 2025 | 29,843 | 1,242,094 | - | 1.7 | 50,435 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 431,000 | 1,271,937 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2025 | 431,000 | 431,000 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.51 per share. | 02 Feb 2024 | 1,288 | 840,937 | - | 1.5 | 1,945 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 590,413 | 590,413 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Alam Kamran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jan 2024 | 590,413 | 842,225 | - | 0 | Common Stock | |
| Taysha Gene Therapies Inc | Alam Kamran | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2023 | 187,582 | 187,582 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 2.33 per share. | 24 Aug 2023 | 33,000 | 258,042 | - | 2.3 | 76,890 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | CHIEF FINANCIAL OFFICER | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 12,462 | 12,462 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 May 2023 | 6,230 | 291,042 | - | - | Common Stock | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 149,900 | 149,900 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 37,384 | 37,384 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 18,691 | 284,812 | - | - | Common Stock | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.47 per share. | 23 Aug 2022 | 3,325 | 266,121 | - | 3.5 | 11,538 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.75 per share. | 18 Aug 2022 | 11,482 | 279,163 | - | 3.8 | 43,058 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.50 per share. | 18 Aug 2022 | 9,717 | 269,446 | - | 3.5 | 34,010 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 3.87 per share. | 18 Aug 2022 | 7,476 | 290,645 | - | 3.9 | 28,932 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Apr 2022 | 40,000 | 40,000 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2022 | 80,000 | 80,000 | - | - | Employee Stock Option (right to buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.35 per share. | 18 Aug 2021 | 11,193 | 319,928 | - | 17.4 | 194,199 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.70 per share. | 18 Aug 2021 | 9,746 | 300,215 | - | 16.7 | 162,758 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.43 per share. | 18 Aug 2021 | 9,354 | 310,574 | - | 16.4 | 153,686 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.14 per share. | 18 Aug 2021 | 2,094 | 298,121 | - | 17.1 | 35,891 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.11 per share. | 18 Aug 2021 | 613 | 309,961 | - | 17.1 | 10,488 | Common Stock |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jan 2021 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Taysha Gene Therapies Inc | Kamran Alam | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Sep 2020 | 331,121 | 331,121 | - | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges